RESPONSE TO NON-FINAL OFFICE ACTION APPL. NO.: 10/520,963 DOCKET NO.: MTV-055.01

## In the Claims:

(currently amended) A compound represented by formula I:

wherein,

n is 1, 3, or 4:

R represents independently for each occurrence H, alkyl, aryl, -CH<sub>2</sub>-aryl, -C(O)-alkyl, -C(O)-aryl, or -Si(alkyl);

 $R^1$  and  $R^2$  are independently H, -CH<sub>2</sub>-aryl, -C(O)-alkyl, -C(O)-aryl, -Si(alkyl)<sub>3</sub>; or  $R^1$  and  $R^2$  taken together are C(CH<sub>3</sub>)<sub>2</sub>, P(O)OH, or P(O)OR<sup>5</sup>;

R3 is amino, -N3, or -NH3X:

R<sup>4</sup> represents independently for each occurrence [[H,]] alkyl, aryl, -CH<sub>2</sub>-aryl, -C(O)-alkyl, -C(O)-aryl, -Si(alkyl)<sub>3</sub>, or -P(O)(OR<sup>5</sup>)<sub>2</sub>;

 $R^5$  represents independently for each occurrence H,  $[[Li^+,]]Li^+$ ,  $Na^+$ ,  $K^+$ ,  $Rb^+$ ,  $Cs^+$ , aryl, or an optionally substituted alkyl group; and

X is a halogen, alkyl carboxylate, or aryl carboxylate.

- (canceled)
- 3. (original) The compound of claim 1, wherein n is 3.
- 4. (original) The compound of claim 1, wherein R is H.

- 5. (original) The compound of claim 1, wherein R<sup>1</sup> and R<sup>2</sup> taken together are P(O)OR<sup>5</sup>.
- 6. (original) The compound of claim 1, wherein R<sup>3</sup> is N<sub>3</sub>.
- (original) The compound of claim 1, wherein R<sup>3</sup> is -NH<sub>3</sub>X.
- (currently amended) The compound of claim 1, wherein R<sup>4</sup> represents independently for each occurrence [[H,]] -CH<sub>2</sub>Ph, or -Si(alkyl)<sub>3</sub>.
- (currently amended) The compound of claim 1, wherein R<sup>4</sup> represents independently for each occurrence [[H,]] -CH<sub>2</sub>Ph, -or P(O)OR<sup>5</sup>; and R<sup>5</sup> is an optionally substituted alkyl group.
- 10. (previously presented) A compound selected from the group consisting of:

PAGE 5

RESPONSE TO NON-FINAL OFFICE ACTION APPL. NO.: 10/520,963
DOCKET NO.: MTV-055.01

## 11. (currently amended) A compound represented by formula II:

wherein.

n is [[1,]] 3, or 4;

R represents independently for each occurrence H, alkyl, aryl, -CH<sub>2</sub>-aryl, -C(O)-alkyl, -C(O)-aryl, or -Si(alkyl)<sub>3</sub>;

R1 is -(CH2)mCH=CH2 or trichloroacetimidate; and

m is 1-6.

- 12. (canceled)
- 13. (original) The compound of claim 11, wherein n is 3.
- 14. (original) The compound of claim 11, wherein m is 3.
- (original) The compound of claim 11, wherein R represents independently for each occurrence -CH<sub>2</sub>-aryl or -Si(alkyl)<sub>3</sub>.
- (original) The compound of claim 11, wherein R represents independently for each occurrence benzyl or -Si(iPr)<sub>3</sub>.
- (previously presented) The compound of claim 11, wherein R<sup>1</sup> is trichloroacetimidate and R represents independently for each occurrence benzyl or -Si(iPr)<sub>3</sub>.
- (previously presented) The compound of claim 11, wherein said compound of formula
   II is selected from the group consisting of:

RESPONSE TO NON-FINAL OFFICE ACTION APPL. NO.: 10/520,963 DOCKET NO.: MTV-055.01

19. (currently amended) A method comprising the step of:

$$R^7 \underset{RO}{\text{RO}} SR^6$$
 admixing a compound represented by 
$$R_3 \qquad \text{with a compound represented}$$

by  $R^2O$  OR , followed by the addition, together or separately of N-

RESPONSE TO NON-FINAL OFFICE ACTION APPL. No.: 10/520,963 DOCKET No.: MTV-055.01

iodosuccinimide and silver triflate, thereby forming a compound represented by

R represents independently for each occurrence H, alkyl, aryl, -CH<sub>2</sub>-aryl, -C(O)-alkyl, -C(O)-aryl, or -Si(alkyl)<sub>3</sub>;

 $R^1$  and  $R^2$  are independently H, -CH<sub>2</sub>-aryl, -C(O)-alkyl, -C(O)-aryl, -Si(alkyl)<sub>3</sub>; or  $R^1$  and  $R^2$  taken together are C(CH<sub>3</sub>)<sub>2</sub>, P(O)OH, or P(O)OR<sup>5</sup>;

R<sup>3</sup> is amino, -N<sub>3</sub>, or -NH<sub>3</sub>X;

R<sup>5</sup> represents independently for each occurrence H, [[Li<sup>+</sup>,]] Li<sup>+</sup>, Na<sup>+</sup>, K<sup>+</sup>, Rb<sup>+</sup>, Cs<sup>+</sup>, aryl, or an optionally substituted alkyl group;

R6 is alkyl or aryl;

R7 is alkyl, aryl, -CH2-aryl, -C(O)-alkyl, -C(O)-aryl, or -Si(alkyl)3; and

X is a halogen, alkyl carboxylate, or aryl carboxylate.

- (original) The method of claim 19, wherein R is -CH<sub>2</sub>-aryl.
- 21. (original) The method of claim 19, wherein R<sup>1</sup> and R<sup>2</sup> taken together are C(CH<sub>3</sub>)<sub>2</sub>.
- 22. (original) The method of claim 19, wherein R<sup>3</sup> is -N<sub>3</sub>.
- 23. (original) The method of claim 19, wherein R<sup>6</sup> is alkyl.
- 24. (original) The method of claim 19, wherein R<sup>7</sup> is -C(O)-alkyl.
- (original) The method of claim 19, wherein R is benzyl, R<sup>1</sup> and R<sup>2</sup> taken together are C(CH<sub>3</sub>)<sub>2</sub>, and R<sup>3</sup> is -N<sub>3</sub>.
- 26. (original) The method of claim 19, wherein R is benzyl,  $R^1$  and  $R^2$  taken together are  $C(CH_3)_2$ ,  $R^3$  is -N<sub>3</sub>, and  $R^6$  is ethyl.
- (previously presented) A method of preparing a tetrasaccharide, comprising the steps of:

DOCKET NO.: MTV-055.01

covalently binding a mannopyranoside to a solid support to provide a first substrate, reacting said first substrate with a mannopyranose trichloroacetimidate to give a disaccharide bound to said solid support, reacting said disaccharide with a mannopyranose trichloroacetimidate to give a triisaccharide bound to said solid support, reacting said trisaccharide with a mannopyranose trichloroacetimidate to give a tetrasaccharide bound to said solid support, and cleaving said tetrasaccharide from said solid support.

- (original) The method of claim 27, wherein said mannopyranoside is bound to said solid support through a glycosidic linkage.
- (original) The method of claim 27, wherein said tetrasaccharide is cleaved from said solid support using Grubbs' catalyst.
- 30. (previously presented) The method of claim 27, wherein said tetrasaccharide is